Optimizing Adjuvant Therapy in HR+/HER2- Early Breast Cancer

Gabriel Hortobagyi, MD


August 19, 2022

Up to 1 in 5 women with HR+/HER2- early breast cancer will experience relapse within 10 years of diagnosis, despite major advances in treatment.

Adjuvant systemic therapy after surgery is routinely given to women to eradicate cancer cells that have escaped the local tumor environment and regional lymph nodes.

Because HR+ breast cancer is heterogeneous, it is necessary to determine a patient's risk for recurrence and death to gauge appropriate adjuvant treatments, says Dr Gabriel Hortobagyi, from the University of Texas MD Anderson Cancer Center in Houston, Texas.

He discusses adjuvant chemotherapy combinations, reporting on who should receive chemotherapy and who is not likely to benefit. He then reports on adjuvant endocrine therapy regimens that are appropriate on the basis of a woman's risk status.

Finally, Dr Hortobagyi looks at newer standards for premenopausal women, setting out when to use tamoxifen and for how long, as well as appropriate use of the CDK 4/6 inhibitor abemaciclib and the poly ADP-ribose polymerase inhibitor olaparib.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.